GIS:ETR
Gilead Sciences, Inc
131,66 EUR
arrow_downward
-0,57%(-0,76) 1 zi
1 oct., 17:35:49 GMT+2 · EUR
search
Toate simbolurile
| Simbol | Preț | Modificare | Modificare % |
|---|
insights_autoSe generează principalele statistici pentru GIS...
Deschide
132,26 EUR
Mare
136,24 EUR
Mic
131,00 EUR
Capitalizarea bursieră
182,89 mld.
Volum mediu
623,00
Volum
3,46 K
Prețul ridicat pe 52 de săptămâni
136,24 EUR
Prețul redus pe 52 de săptămâni
92,41 EUR
Nr. de angajați
17 K
Deschide
132,26 EUR
Mare
136,24 EUR
Mic
131,00 EUR
Capitalizarea bursieră
182,89 mld.
Volum mediu
623,00
Volum
3,46 K
Prețul ridicat pe 52 de săptămâni
136,24 EUR
Prețul redus pe 52 de săptămâni
92,41 EUR
Nr. de angajați
17 K
Subiecte de știri
Din surse web și de la parteneri de știri
Barron's
·
acum 51 de minute
More Upside Awaits for Gilead Sciences Stock. Stay Invested.
MarketBeat
·
acum 9 ore
Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD
AD HOC NEWS
·
acum 9 ore
Gilead Sciences stock after-hours at EUR 131.85: plus 0.62 percent after the Xetra close
Yahoo Finance
·
acum 15 ore
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Despre Gilead Sciences, Inc
Director executivDaniel O'Day
Angajați17 K
Înființată la22 iun. 1987
SediuFoster City, California, Statele Unite ale Americii
Domeniu-
Sitegilead.com